Resultado de la Oferta Abierta
NO PARA PUBLICACIÓN, DISTRIBUCIÓN O LIBERACIÓN TOTAL O PARCIALMENTE, DIRECTA O INDIRECTA, EN O EN LOS ESTADOS UNIDOS, AUSTRALIA, CANADÁ, NUEVA ZELANDA, JAPÓN O LA REPÚBLICA DE SUDÁFRICA O EN CUALQUIER OTRA JURISDICCIÓN EN LA QUE SE PUEDEN REALIZAR OFERTAS O VENTAS. PROHIBIDO POR LA LEY APLICABLE. ESTE ANUNCIO NO ES UNA OFERTA DE VENDA NI UNA SOLICITUD DE COMPRA DE VALORES EN NINGUNA JURISDICCIÓN. NI ESTE ANUNCIO NI NADA DE LO CONTENIDO EN EL PRESENTE FORMARÁ LA BASE DE CUALQUIER OFERTA O COMPROMISO EN NINGUNA JURISDICCIÓN, NI SERÁ CONSECUENCIA DE NINGUNA OFERTA O COMPROMISO.
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF EU REGULATION NO. 596/2014 AS IT FORMS PART OF DOMESTIC LAW IN THE UNITED KINGDOM BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018 ("UK MAR"). UPON THE PUBLICATION OF THIS ANNOUNCEMENT, THIS INSIDE INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN.
19 de diciembre 2023
Scancell Holdings plc
("Scancell" o la "Empresa")
Resultado de la Oferta Abierta
Notificación de PDMR
Scancell Holdings plc (AIM: SCLP), the developer of novel immunotherapies for the treatment of cancer and infectious disease, today announces the results of the open offer to shareholders (the "Oferta abierta"), the commencement of which was announced by the Company on 30 November 2023 (the "Anuncio de lanzamiento").
The Open Offer closed for acceptances at 11.00 a.m. on 18 December 2023. The Company is pleased to announce that it has received valid applications under the Open Offer (including under the Excess Application Facility) in respect of 11,136,877 Open Offer Shares (the "New Open Offer Shares") at 11 pence per New Open Offer Share from Qualifying Shareholders raising gross proceeds from the Open Offer of £1.2 million.
The Open Offer is conditional upon Second Admission occurring. Application has been made to the London Stock Exchange for the New Open Offer Shares to be admitted to trading on AIM. It is expected that Second Admission will become effective and dealings will commence in the New Open Offer Shares at 8.00 a.m. on 20 December 2023.
This announcement should be read in conjunction with the full text of the circular published on 4 December 2023 (the "Circular"). The Circular is also available on the Company's website at www.Scancell.co.uk.
Total de derechos de voto
Following Second Admission, the Company's enlarged issued ordinary share capital will be 927,819,977. This figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.
Confirmation of Gross Proceeds Raised
The Company has raised gross proceeds of approximately £11.9 million in aggregate (before expenses) through the Capital Raise (as first announced by the Company in the Launch Announcement). This is comprised of (i) gross proceeds of approximately £10.7 million in aggregate through the Placing and the Subscription with significant participation from both existing and new healthcare specialist investors and (ii) gross proceeds of approximately £1.2 million through the Open Offer reflecting renewed support from existing shareholders.
Los términos en mayúscula utilizados en este anuncio tienen el significado definido en el Anuncio de lanzamiento, a menos que se indique lo contrario.
A los efectos de UK MAR, la persona responsable de organizar la publicación de este anuncio en nombre de la Compañía es la Profesora Lindy Durrant, Directora Ejecutiva.
Para más información, póngase en contacto con:
|
Sobre Scancell
Scancell es una empresa biofarmacéutica en etapa clínica que está aprovechando su investigación patentada, acumulada durante muchos años de estudio del sistema inmunológico adaptativo humano, para generar medicamentos novedosos para tratar importantes necesidades no cubiertas en cáncer y enfermedades infecciosas. La Compañía está construyendo una cartera de productos innovadores mediante la utilización de sus cuatro plataformas tecnológicas: Moditope® e ImmunoBody® para vacunas y GlyMab® y AvidiMab® para anticuerpos.
Las respuestas inmunes adaptativas incluyen anticuerpos y células T (CD4 y CD8), los cuales pueden reconocer células dañadas o infectadas. Para destruir dichas células cancerosas o infectadas, Scancell utiliza vacunas para inducir respuestas inmunitarias o anticuerpos monoclonales (mAb) para redirigir las células inmunitarias o los fármacos. El enfoque único de la compañía es que sus productos innovadores apuntan a modificaciones de proteínas y lípidos. Para las vacunas (Moditope® e ImmunoBody®), esto incluye citrulinación y homocitrulinación de proteínas, mientras que su cartera de mAb se dirige a los glicanos o azúcares que se agregan a las proteínas y/o lípidos (GlyMab®) o mejora la potencia de los anticuerpos y su capacidad para actuar directamente. matar células tumorales (AvidiMab®).
For further details, please see the Company's website: www.Scancell.co.uk
Noticia importante
This announcement and the information contained in it is restricted and is not for release, publication or distribution, directly or indirectly, in whole or in part, in, into or from the United States, Australia, Canada, New Zealand, Japan or the Republic of South Africa or any other jurisdiction in which the same would constitute a violation of the relevant laws or regulations of that jurisdiction (each, a "Jurisdicción restringida"). The securities mentioned herein have not been, and will not be, registered under the US Securities Act of 1933, as amended (the "Ley de valores"). The New Open Offer Shares may not be offered or sold in the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. There has been no public offer of securities of the Company in the United States.
This announcement has been issued by, and is the sole responsibility of, the Company. No representation or warranty express or implied, is or will be made as to, or in relation to, and no responsibility or liability is or will be accepted by Stifel, WG Partners or by any of their respective affiliates, directors, officers, employees, advisers or agents as to or in relation to, the accuracy or completeness of this announcement or any other written or oral information made available to or publicly available to any interested party or its advisers, and any liability therefore is expressly disclaimed. Neither Stifel nor WG Partners has authorised the contents of, or any part of, this announcement.
Stifel, which is authorised and regulated in the United Kingdom by the FCA, is acting exclusively for the Company and no-one else in connection with the Capital Raise and will not regard any other person as
a client in relation to the Capital Raise and will not be responsible to anyone other than the Company for providing the protections afforded to its clients or for providing advice in relation to the Capital Raise
or any other matter referred to herein. Its responsibilities as nominated advisor and joint broker to the Company are owed to the London Stock Exchange and the Company and its responsibilities as Joint Bookrunner are owed to the Company, respectively, and not to any other person including, without limitation, in respect of any decision to acquire New Open Offer Shares in reliance on any part of this announcement.
WG Partners, which is authorised and regulated in the United Kingdom by the FCA, is acting exclusively for the Company and no-one else in connection with the Capital Raise and will not regard any other person as a client in relation to the Capital Raise and will not be responsible to anyone other than the Company for providing the protections afforded to its clients or for providing advice in relation to the Capital Raise or any other matter referred to herein. Its responsibilities as Joint Bookrunner are owed to the Company and not to any other person including, without limitation, in respect of any decision to acquire New Open Offer Shares in reliance on any part of this announcement.
No public offering of New Open Offer Shares has been made in the United Kingdom, any Restricted Jurisdiction or elsewhere. The distribution of this announcement and the offering of the New Open Offer Shares in certain jurisdictions may be restricted by law. No action has been taken by the Company, Stifel or WG Partners that would have permitted an offering of such New Open Offer Shares or possession or distribution of this announcement or any other offering or publicity material relating to such New Open Offer Shares in any jurisdiction where action for that purpose is required.
The information in this announcement may not be forwarded or distributed to any other person and may not be reproduced in any manner whatsoever. Any forwarding, distribution, reproduction, or disclosure of this information in whole or in part is unauthorised. Failure to comply with this directive may result in a violation of the Securities Act or the applicable laws of other jurisdictions.
It is expected that the New Open Offer Shares in the Company to be issued pursuant to the Open Offer will not be admitted to trading on any stock exchange other than to trading on AIM, a market operated by the London Stock Exchange. This announcement is not an offering document, prospectus, prospectus equivalent document or AIM admission document. No offering document, prospectus, prospectus equivalent document or AIM admission document was required in connection with the Open Offer and no such document has been or was prepared or submitted to be approved by the FCA or submitted to the London Stock Exchange in relation to the Open Offer.
Neither the content of the Company's website nor any links on the Company's website is incorporated
in, or forms part of, this announcement.
As a result of Dr Sally Adams' participation in the Open Offer, the following notification is included below as required under UK MAR.
NOTIFICACIÓN Y DIVULGACIÓN PÚBLICA DE LAS OPERACIONES POR PARTE DE LAS PERSONAS QUE DESPIDEN
RESPONSABILIDADES DE LA DIRECCIÓN Y PERSONAS MUY ASOCIADAS CON ELLAS
1 | Detalles de la persona que cumple con las responsabilidades de gestión / persona estrechamente asociada | |
a) | Nombre | Dr Sally Adams |
2 | Razón de la notificación | |
a) | Posición / estado | Chief Development Officer and PDMR |
b) | Notificación inicial / Enmienda | Notificación inicial |
3 | Datos del emisor, participante en el mercado de derechos de emisión, plataforma de subastas, subastador o supervisor de subastas | |
a) | Nombre | Scancell Holdings plc |
b) | LEY | 2138008RXEG856SNP666 |
4 | Detalles de la (s) transacción (es): sección que se repetirá para (i) cada tipo de instrumento; (ii) cada tipo de transacción; (iii) cada fecha; y (iv) cada lugar donde se han realizado transacciones | |
a) | Descripción del instrumento financiero, tipo de instrumento | Acciones ordinarias de 0.1 peniques cada una en el capital de la Compañía |
b) | Código de identificación | GB00B63D3314 |
c) | Naturaleza de la transacción | Participation in the open offer of ordinary shares of 0.1 pence each in the capital of the Company |
d) | Precio (s) y volumen (es) | 9,091 acciones ordinarias a £0.11 libras por acción |
e) | Información agregada - Volumen agregado - Precio |
N / A (transacción única)
|
f) | Fecha de la transacción | 19 de diciembre 2023 |
g) | Lugar de la transacción | Fuera de un centro de negociación |
RNS puede usar su dirección IP para confirmar el cumplimiento de los términos y condiciones, para analizar cómo interactúa con la información contenida en esta comunicación y para compartir dicho análisis de forma anónima con otros como parte de nuestros servicios comerciales. Para obtener más información sobre cómo RNS y la Bolsa de Valores de Londres utilizan los datos personales que nos proporciona, consulte nuestra Política de privacidad.